Most people taking Wegovy at the full maintenance dose lose about 15% of their body weight over roughly 16 months. For someone starting at 250 pounds, that translates to approximately 37 pounds. But that number comes from clinical trials with close monitoring and consistent use. Real-world results tend to be lower, and several factors influence where you’ll land on the spectrum.
Clinical Trial Results
The landmark trials for Wegovy (called the STEP trials) tested the drug over 68 weeks, about 16 months. Adults without type 2 diabetes lost an average of 14.9% of their body weight on the 2.4 mg maintenance dose. For context, participants on placebo lost only about 2.4%, so the drug itself accounted for roughly 12 percentage points of that loss.
Results were more modest for people with type 2 diabetes. In that group, average weight loss was 9.6% over the same period, compared to 3.4% with placebo. Diabetes changes how the body regulates metabolism and insulin, which appears to blunt some of the drug’s weight loss effect, though nearly 69% of participants with diabetes still lost at least 5% of their body weight.
Adolescents aged 12 to 17 saw strong results as well. Over 68 weeks, teens on Wegovy reduced their BMI by an average of 16.1%, while those on placebo saw essentially no change.
What a Typical Timeline Looks Like
Wegovy uses a slow dose escalation to reduce side effects. You start at 0.25 mg per week and increase every four weeks: 0.5 mg, then 1 mg, then 1.7 mg, before reaching the full 2.4 mg maintenance dose around week 17. Those early doses are not therapeutic for weight loss. They’re designed to let your body adjust.
Most people notice meaningful weight loss starting around months two and three, with roughly 6% of body weight gone by the three-month mark. The loss continues to accelerate once you reach the maintenance dose, with results in clinical trials reaching the 15% range by 68 weeks. Weight loss typically plateaus somewhere between months 12 and 16, meaning the drug doesn’t produce indefinite loss. Your body reaches a new set point and stabilizes.
Real-World Results Are Lower
Clinical trials represent best-case scenarios: participants are closely monitored, follow structured diets, and stay on the full dose. In practice, things look different. A large observational study of nearly 6,500 people found that average weight loss with semaglutide at one year was 7.7%, roughly half of what the trials showed.
The gap isn’t because the drug stops working. It’s mostly because people stop taking it early or never reach the highest dose. When researchers isolated the people who stayed on high maintenance doses (1.7 mg or 2.4 mg) for the full year, their average loss was 13.7%, much closer to the trial numbers. Staying on the medication at full dose is the single biggest factor in how much weight you lose.
Why Some People Lose Less
In clinical trials, more than 13% of participants on Wegovy were considered non-responders, meaning they didn’t lose at least 5% of their body weight within the first three months. Several factors can limit how well the drug works for you.
- Type 2 diabetes reduces the average loss by about 5 percentage points compared to people without it.
- Not reaching full dose due to side effects (primarily nausea and vomiting) keeps some people at lower, less effective doses. The 1.7 mg dose is now approved as an alternative maintenance dose, and while it still produces meaningful weight loss, it delivers somewhat less than 2.4 mg.
- Diet and activity level still matter. Wegovy is approved specifically for use alongside a reduced-calorie diet and increased physical activity. The drug reduces appetite, but it doesn’t override consistent caloric surplus.
How Wegovy Produces Weight Loss
Semaglutide mimics a gut hormone called GLP-1 that your body naturally releases after eating. This hormone activates receptors in the parts of your brain that control hunger and fullness. Wegovy essentially amplifies that “I’ve had enough” signal, making you feel satisfied with less food. Most people describe it as a quieting of the constant background noise of food cravings rather than a dramatic suppression of hunger.
The drug also slows stomach emptying, so meals keep you full longer. The combined effect is a significant, sustained reduction in calorie intake without requiring the kind of willpower that makes most diets fail.
What Happens After Stopping
Weight regain after stopping Wegovy is significant and well documented. A systematic review published in The BMJ found that people regain an estimated 9.9 kg (about 22 pounds) within the first year after stopping newer drugs like semaglutide. The projected timeline for returning to baseline weight was approximately 1.5 years after stopping treatment.
This doesn’t mean the drug “didn’t work.” It means obesity is a chronic condition, and the biological signals that drive weight regain return when the medication is removed, similar to how blood pressure rises again when you stop taking blood pressure medication. Most prescribers now treat Wegovy as a long-term or indefinite therapy rather than a short course.
Who Can Get a Prescription
Wegovy is FDA-approved for adults with a BMI of 30 or higher (classified as obesity), or a BMI of 27 or higher with at least one weight-related health condition such as high blood pressure, type 2 diabetes, or high cholesterol. It’s also approved for adolescents aged 12 and older with obesity. The injectable form and a newer oral tablet form carry the same eligibility criteria for adults.